4-Benzyl-1-[2-(4-hydroxyphenoxy)ethyl]piperidine-3,4-diol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-Benzyl-1-[2-(4-hydroxyphenoxy)ethyl]piperidine-3,4-diol
• 化学式: C₂₀H₂₅NO₄
• 分子量: 343.4
• InChiKey: QDLSQZUNQXEAFR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  73.2
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• Neuroprotective substituted piperidine compounds with activity as NMDA NR2B subtype selective antagonists
  申请人：——

  公开号：US20010047014A1

  公开（公告）日：2001-11-29

  The invention relates to a compound of the formula 1 its R,R-, S,S-enantiomers and racemic mixtures thereof and to their pharmaceutically acceptable acid addition salts. The compound of formula I and its R,R- and S,S-enantiomers may be used as medicaments for the treatment of diseases, wherein the therapeutic indications include acute forms of neurodegeneration caused by stroke or brain trauma; chronic forms of neurodegeneration such as Alzheimer's disease, Parkinson's disease, Huntington's disease or ALS (amyotrophic lateral sclerosis); neurodegeneration associated with bacterial or viral infections, and, diseases such as schizophrenia, anxiety, depression and chronic/acute pain.

  本发明涉及一种公式1的化合物，其R，R-，S，S-对映体及其光学异构体混合物及其药学上可接受的酸盐。公式I的化合物及其R，R-和S，S-对映体可用作药物治疗疾病，其中治疗适应症包括由中风或脑外伤引起的神经退行性急性形式；阿尔茨海默病、帕金森病、亨廷顿病或肌萎缩侧索硬化等慢性神经退行性疾病；与细菌或病毒感染相关的神经退行性疾病以及精神分裂症、焦虑症、抑郁症和慢性/急性疼痛等疾病。
• NMDA Receptor Antagonists for Neuroprotection
  申请人：Liotta Dennis C.

  公开号：US20090253710A1

  公开（公告）日：2009-10-08

  Provided are compounds, pharmaceutical compositions and methods of treatment or prophylaxis of disorders associated with NMDA receptor activity, including neuropathic pain, stroke, traumatic brain injury, epilepsy, and related neurologic events or neurodegeneration. Compounds are of the general Formula I, or a pharmaceutically acceptable salt, ester, prodrug or derivative thereof are provided: wherein: each (L) k -Ar 1 is a substituted or unsubstituted, mono or bicyclic aryl or heteroaryl; W is a bond, alkyl, or alkenyl; X is a bond, NR 1 or O and each R 1 and R 2 is independently H, alkyl, alkenyl or aralkyl or R 1 and R 2 taken together form a 5-8 membered ring; R 3− R 6 are selected from certain specific substituents or a carbonyl; Y is a bond, O, S, SO, SO 2 , CH 2 , NH, N(alkyl), or NHC(═O); and Z is OH, NR 6 R 7 , NR 8 SO 2 (alkyl), NR 8 C(O)NR 6 R 7 , NR 8 C(O)O(alkyl), NR 8 -dihydrothiazole, or NR 8 -dihydroimidazole or wherein Z can fuse with Ar 2 to form selected heterocycles.

  提供了与NMDA受体活性相关的疾病治疗或预防的化合物、制药组合物和方法，包括神经病理性疼痛、中风、创伤性脑损伤、癫痫和相关的神经事件或神经退行性疾病。提供了通式I的化合物或其药学上可接受的盐、酯、前药或衍生物: 其中：每个（L）k-Ar1是取代或未取代的、单环或双环芳基或杂环芳基；W是键、烷基或烯基；X是键、NR1或O，每个R1和R2是独立的H、烷基、烯基或芳基烷基，或R1和R2共同形成5-8成员环；R3-R6选自特定的取代基或羰基；Y是键、O、S、SO、SO2、CH2、NH、N（烷基）或NHC（═O）；Z是OH、NR6R7、NR8SO2（烷基）、NR8C（O）NR6R7、NR8C（O）O（烷基）、NR8-二氢噻唑或NR8-二氢咪唑，或Z可以与Ar2融合形成选择的杂环。
• 4-BENZYL-1- 2-(4-HYDROXY-PHENOXY)-ETHYL]-PIPERIDINE-3,4-DIOL
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP1278730A2

  公开（公告）日：2003-01-29
• 4-BENZYL-1-[2-(4-HYDROXY-PHENOXY)-ETHYL]-PIPERIDINE-3,4-DIOL
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP1278730B1

  公开（公告）日：2005-12-21
• NMDA Receptor Antagonists for the Treatment of Neuropsychiatric Disorders
  申请人：Dingledine Raymond J.

  公开号：US20110160223A1

  公开（公告）日：2011-06-30

  Provided are pharmaceutical compositions and methods of treatment or prophylaxis of certain neuropsychiatric conditions, in particular mood disorders. The compounds are of the general Formula I-V as described herein.